MA29406B1 - Vaccin toxoide alpha de c. perfringens - Google Patents

Vaccin toxoide alpha de c. perfringens

Info

Publication number
MA29406B1
MA29406B1 MA30321A MA30321A MA29406B1 MA 29406 B1 MA29406 B1 MA 29406B1 MA 30321 A MA30321 A MA 30321A MA 30321 A MA30321 A MA 30321A MA 29406 B1 MA29406 B1 MA 29406B1
Authority
MA
Morocco
Prior art keywords
perfringens
vaccines
alpha
toxoid vaccine
alpha toxoid
Prior art date
Application number
MA30321A
Other languages
English (en)
Inventor
Huchappa Jayappa
Kevin O'connell
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36820082&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29406(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of MA29406B1 publication Critical patent/MA29406B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION A TRAIT À DES VACCINS COMPORTANT DES TOXOÏDES C.PERFRINGENS DE TYPE ALPHA, DES FRAGMENTS ANTIGÉNIQUES DE CELLES-CI, DES FRAGMENTS ANTIGÉNIQUES INACTIVÉS DE TOXINES C.PERFRINGENS DE TYPE ALPHA, OU TOUTE COMBINAISON DE CEUX-CI. LA PRÉSENTE INVENTION A ÉGALEMENT TRAIT À DES PROCÉDÉS D'UTILISATION DE CES VACCINS POUR LA PROTECTION D'ANIMAUX CONTRE DES MALADIES CLOSTRIDIALES. LA PRÉSENTE INVENTION A TRAIT EN OUTRE À DES PROCÉDÉS DE FABRICATION DE TELS VACCINS.
MA30321A 2005-04-18 2007-10-26 Vaccin toxoide alpha de c. perfringens MA29406B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67228905P 2005-04-18 2005-04-18

Publications (1)

Publication Number Publication Date
MA29406B1 true MA29406B1 (fr) 2008-04-01

Family

ID=36820082

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30321A MA29406B1 (fr) 2005-04-18 2007-10-26 Vaccin toxoide alpha de c. perfringens

Country Status (25)

Country Link
US (2) US8980283B2 (fr)
EP (1) EP1874344B1 (fr)
JP (2) JP5243951B2 (fr)
KR (1) KR20080005277A (fr)
CN (1) CN101198352B (fr)
AR (1) AR054251A1 (fr)
AU (1) AU2006236365B2 (fr)
BR (1) BRPI0610843B1 (fr)
CA (1) CA2606180C (fr)
CR (1) CR9443A (fr)
DK (1) DK1874344T3 (fr)
ES (1) ES2583484T3 (fr)
IL (1) IL186701A0 (fr)
MA (1) MA29406B1 (fr)
MX (1) MX2007013053A (fr)
MY (1) MY149604A (fr)
NZ (1) NZ562637A (fr)
PE (1) PE20061398A1 (fr)
RU (1) RU2434638C2 (fr)
SG (1) SG186672A1 (fr)
TN (1) TNSN07387A1 (fr)
TW (1) TWI311057B (fr)
UA (1) UA98099C2 (fr)
WO (1) WO2006113772A1 (fr)
ZA (1) ZA200709516B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
AU2007245198B2 (en) * 2006-03-30 2010-08-12 Zoetis Services Llc Methods and compositions for vaccination of poultry
MX2008013451A (es) * 2006-04-17 2008-10-30 Schering Plough Ltd Organismos clostridium atenuados recombinantes y vacuna.
AU2007313819A1 (en) * 2006-10-27 2008-05-08 Dow Agrosciences Llc Poultry vaccine, for necrotic enteritis, comprising a mutated Clostridium perfringens alpha toxin antigen, and methods of producing the vaccine
CA2669765A1 (fr) * 2006-11-20 2008-05-29 Intervet International B.V. Utilisation d'une bacterie de clostridium perfringens type c pour la fabrication d'un vaccin
CA2629790C (fr) * 2007-04-12 2015-06-30 Nutratech Anticorps aviaires antimethanogenes permettant de diminuer la production de methane
CA2685533C (fr) * 2007-06-22 2019-07-02 University Of Guelph Vaccin contre <i>clostridium perfringens</i>
US8956628B2 (en) * 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
US8293101B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
WO2011103465A2 (fr) * 2010-02-20 2011-08-25 Alexey Gennadievich Zdanovsky Compositions antigéniques comprenant la neurotoxine botulique et procédés associés
WO2011151941A1 (fr) * 2010-06-04 2011-12-08 国立大学法人東京大学 Composition présentant une activité d'induction de la prolifération ou de l'accumulation de cellule t régulatrice
CN102008720B (zh) * 2010-07-20 2015-02-25 东北农业大学 抗魏氏梭菌病转基因植物疫苗及其制作方法
WO2013091895A1 (fr) * 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Nouveau procédé pour la fabrication de protéines di-chaînes pour utilisation dans les êtres humains
CN102657683B (zh) * 2012-06-02 2014-05-07 哈尔滨工业大学 一种免疫类毒素的制备方法
CN102698259B (zh) * 2012-06-12 2017-02-08 北京中海生物科技有限公司 一种鸡坏死性肠炎(a型)灭活疫苗制备方法
CN102688484B (zh) * 2012-06-13 2016-03-30 北京中海生物科技有限公司 一种鸡坏死性肠炎(c型)灭活疫苗的生产方法
EP2911688B1 (fr) 2012-10-26 2019-10-16 Intervet International B.V. Vaccins de protection croisée contre la salmonelle
CN103463632B (zh) * 2013-09-05 2016-01-06 山东农业大学 牛羊肠毒血症的d型产气荚膜梭菌类毒素疫苗的制备方法
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo
CN103861094A (zh) * 2014-03-27 2014-06-18 山东农业大学 一种产气荚膜梭菌α毒素基因工程疫苗及其应用
CN104131022A (zh) * 2014-08-01 2014-11-05 中国农业科学院兰州兽医研究所 产气荚膜梭菌α、β1、β2、ε毒素共表达载体及其构建方法和表达方法
CN104531731B (zh) * 2014-12-15 2018-06-26 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体7D
CN104531730B (zh) * 2014-12-15 2018-07-17 中国人民解放军军事医学科学院军事兽医研究所 产气荚膜梭菌α毒素人源化单链抗体8B
CN104531867B (zh) * 2014-12-25 2017-03-29 湖北省农业科学院畜牧兽医研究所 产气荚膜梭菌肠毒素阳性菌双重荧光定量pcr快速检测试剂盒
EP3112474A1 (fr) * 2015-06-29 2017-01-04 Evonik Degussa GmbH Procédé de détection d'entérite nécrotique aviaire
EP3571288A4 (fr) 2017-01-23 2020-12-02 University of Florida Research Foundation, Incorporated Induction d'immunité protectrice contre des antigènes
WO2018159476A1 (fr) * 2017-02-28 2018-09-07 一般財団法人阪大微生物病研究会 Vaccin polyvalent
WO2018218360A1 (fr) * 2017-05-31 2018-12-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Agriculture And Agri-Food Vaccin contre l'entérite nécrotique chez la volaille
WO2018224595A1 (fr) * 2017-06-09 2018-12-13 Hipra Scientific, S.L.U. Vaccin comprenant des anatoxines de clostridium
EP3661547A4 (fr) * 2017-08-04 2021-06-09 University of Florida Research Foundation, Incorporated Induction d'une immunité protectrice contre des antigènes
CN107596361B (zh) * 2017-09-12 2020-08-14 浙江海隆生物科技有限公司 牛a型产气荚膜梭菌的亚单位疫苗及其制备方法和应用
CN107875377B (zh) * 2017-11-06 2020-01-03 山东农业大学 一种e型产气荚膜梭菌类毒素疫苗的制备方法
CN109954135B (zh) * 2017-12-25 2023-01-31 金宇保灵生物药品有限公司 牛a型产气荚膜梭菌灭活类毒素疫苗及其制备方法
CN108578686B (zh) * 2018-04-23 2022-07-01 杨凌凯瑞生物科技有限公司 一种制备羊梭菌病基因工程亚单位疫苗的方法
CN109111509B (zh) * 2018-09-19 2021-08-13 天康制药(苏州)有限公司 腐败梭菌α毒素突变体、表达其的基因、制备方法和腐败梭菌疫苗
CN111500482B (zh) * 2019-01-31 2023-09-05 内蒙古金宇保灵生物技术研究院有限公司 一种羊a型产气荚膜梭菌菌株及其灭活疫苗和疫苗制备方法
CN109943507B (zh) * 2019-03-26 2021-08-17 中国兽医药品监察所 一种兽用a型产气荚膜梭菌类毒素的制备方法及其应用
CN110041437B (zh) * 2019-04-29 2020-12-25 中国兽医药品监察所 一种无毒性破伤风毒素和诺维梭菌α毒素重组融合蛋白

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2257230B1 (fr) * 1973-09-14 1976-11-19 Agronomique Inst Nat Rech
SU627610A1 (ru) * 1977-09-30 1980-02-05 Zemlyakova V P Препарат землаково в.п. против клюстридиозов животных и птиц
MX9302964A (es) * 1992-05-20 1995-01-31 Secr Defence Vacunas de clostridium perfringens.
DK0692974T4 (da) * 1993-03-29 2007-10-01 Pfizer Multikomponent clostridiumvacciner hvor saponin anvendes som adjuvans
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
CN101596312A (zh) * 2002-05-21 2009-12-09 先灵-普劳有限公司 孢子纲物种体外培养的方法及其用途
ATE505538T1 (de) 2003-06-09 2011-04-15 Corixa Corp Dna-vektoren
MXPA06001764A (es) 2003-08-14 2006-07-03 Merial Ltd Composiciones y vacunas que contienen antigeno(s) de cryptosporidium parvum y de otro patogeno.
GB2434367B (en) 2004-10-05 2010-05-12 Diversa Corp Improved vaccines
MY149604A (en) * 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine
CA2669765A1 (fr) * 2006-11-20 2008-05-29 Intervet International B.V. Utilisation d'une bacterie de clostridium perfringens type c pour la fabrication d'un vaccin

Also Published As

Publication number Publication date
MX2007013053A (es) 2008-01-14
BRPI0610843B1 (pt) 2021-11-30
RU2434638C2 (ru) 2011-11-27
AU2006236365A1 (en) 2006-10-26
UA98099C2 (uk) 2012-04-25
SG186672A1 (en) 2013-01-30
NZ562637A (en) 2010-06-25
WO2006113772A1 (fr) 2006-10-26
MY149604A (en) 2013-09-13
KR20080005277A (ko) 2008-01-10
AR054251A1 (es) 2007-06-13
TW200719910A (en) 2007-06-01
JP5243951B2 (ja) 2013-07-24
EP1874344B1 (fr) 2016-06-08
JP2008536936A (ja) 2008-09-11
TWI311057B (en) 2009-06-21
CN101198352A (zh) 2008-06-11
CR9443A (es) 2008-02-20
EP1874344A1 (fr) 2008-01-09
ZA200709516B (en) 2008-11-26
JP2012062330A (ja) 2012-03-29
US20060233825A1 (en) 2006-10-19
PE20061398A1 (es) 2007-01-15
IL186701A0 (en) 2008-02-09
DK1874344T3 (en) 2016-09-19
BRPI0610843A2 (pt) 2010-07-27
CA2606180A1 (fr) 2006-10-26
AU2006236365B2 (en) 2012-02-02
RU2007142337A (ru) 2009-05-27
CN101198352B (zh) 2011-07-27
CA2606180C (fr) 2016-09-13
US20150140033A1 (en) 2015-05-21
ES2583484T3 (es) 2016-09-21
US8980283B2 (en) 2015-03-17
US9662380B2 (en) 2017-05-30
TNSN07387A1 (en) 2009-03-17

Similar Documents

Publication Publication Date Title
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
MA29714B1 (fr) Vaccin
WO2005116270A3 (fr) Composition de vaccin contre le virus de la grippe et ses methodes d&#39;utilisation
ECSP034447A (es) Vacunas para proteccion de espectro amplio contra enfermedades causadas por neisseria meningitidis
ATE556718T1 (de) Neisseria meningitidis kombinationimpfstoffe
MA30065B1 (fr) Vaccin
WO2007030810A3 (fr) Moniteur de sang total multiparametrique et procede associe
IN2014DN08830A (fr)
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
WO2007006712A3 (fr) Vaccin de sous-unite de mycoplasma
WO2006091722A3 (fr) Vaccination amplifiee par alkyle-glycosides
MA29459B1 (fr) Vaccins
PT1154790E (pt) Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
CR11307A (es) Vacunas
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
GB2444676A (en) Adjuvanted vaccine
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
SG163571A1 (en) Rotavirus vaccine inducing heterotypic cross protection
AR065765A1 (es) Composicion de vacuna para el tratamiento de enfermedades infecciosas respiratorias
WO2007086898A3 (fr) Procedes et compositions relatives a des glycoproteines des spores du charbon
WO2010080188A3 (fr) Vaccin ciblé par épitope contre le charbon
EP1667634A4 (fr) Vaccin contre l&#39;anthrax
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella